IntelliCyt, an Albuquerque, NM-based provider of integrated platforms to accelerate drug discovery, antibody discovery and immunology, closed 7.4m financing round.
The financing included $5.4m in venture capital and $2m in debt facility.
The vc round was led by Arboretum Ventures with participation from other current investors Prolog Ventures, Verge Fund, and New Mexico Community Capital. The debt financing was led by Oxford Finance.
Led by R. Terry Dunlay, President and CEO, IntelliCyt develops a platform featuring software-assisted automation, analysis, and experiment-level visualization tools for the study of cells enhancing suspension-cell screening workflows from sample preparation through results. It enables rapid, multiplexed analysis of cells and beads in suspension in 96, 384, and 1536 well plates. The proprietary sample delivery system enables the miniaturization of assays to conserve precious sample and use less reagent per well.